Triple Antibiotic Paste (TAP) as an Intracanal Medicament

Composition

Mechanism of Action

• Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication
• Metronidazole is reduced by anaerobic bacteria into reactive intermediates that cause DNA strand breakage - effective against strict anaerobes that predominate in necrotic root canals
• Minocycline blocks the 30S ribosomal subunit, halting protein synthesis; also has anti-inflammatory effects and can inhibit matrix metalloproteinases (MMPs)

Clinical Applications

1. Conventional Endodontic Treatment

• Used as an inter-appointment intracanal dressing for infected root canals, particularly in cases of acute apical abscess, chronic apical periodontitis, and refractory infections unresponsive to calcium hydroxide
• Applied after irrigation and canal shaping; left in place for 1-4 weeks

2. Regenerative Endodontic Procedures (REPs)

• Disinfects the root canal system without mechanical instrumentation (preserving thin dentinal walls)
• Preserves the survival of dental pulp stem cells (DPSCs) and stem cells from the apical papilla (SCAPs) when used at low concentration (0.1 mg/mL)
• Creates a sterile environment permissive for scaffold placement (blood clot, platelet-rich fibrin) and subsequent root maturation

3. LSTR Therapy (Lesion Sterilization and Tissue Repair)

Preparation and Placement

• Mixed to a creamy paste consistency using a suitable vehicle (macrogol + propylene glycol, or saline)
• Delivered into canals with a lentulo spiral, endodontic explorer, or ultrasonic activation
• Placed to 3-4 mm short of the apex to avoid periapical tissue toxicity
• Sealed with a temporary restorative material
• Concentration for REPs: reduced to 0.1 mg/mL (vs. 1 g/mL for conventional use) to reduce cytotoxicity and tooth discoloration

Advantages

1. Broad-spectrum antimicrobial activity against aerobic, anaerobic, and facultative organisms
2. Deep penetration into dentinal tubules - ciprofloxacin particularly penetrates well
3. Effective against biofilm - all three components have some anti-biofilm activity
4. No mechanical instrumentation required - ideal for fragile immature roots
5. Promotes periapical healing - minocycline's anti-inflammatory properties assist
6. Supports stem cell viability at low concentrations for REPs

Disadvantages and Limitations

1. Tooth discoloration - minocycline chelates with iron in dentine, producing gray-brown staining. This is the major clinical drawback, especially in anterior teeth
   • Solution: Replace minocycline with cefaclor or clindamycin (forming double antibiotic paste - DAP) or use low concentrations
2. Cytotoxicity at high concentrations - toxic to fibroblasts, osteoblasts, and SCAPs at the conventional 1 g/mL dose
3. Antibiotic resistance concerns with repeated or prolonged use
4. Hypersensitivity reactions (rare) to any of the three components
5. Incomplete sterilization - does not reliably eliminate E. faecalis in some studies
6. No hard tissue barrier formation by itself - requires subsequent scaffold placement in REPs

Comparison with Other Intracanal Medicaments

Evidence from Recent Literature

• TAP 1-year success rate: 96.7% (95% CI: 94.8%-98.0%)
• Calcium hydroxide: 97.4% (95% CI: 93.9%-99.1%)
• DAP: 84.2% (95% CI: 73.2%-92.0%)
• TAP and Ca(OH)₂ are statistically equivalent; both are superior to DAP
• Evidence quality: HIGH for TAP and Ca(OH)₂, LOW for DAP

Current Recommendations

• For REPs (AAE/ESE guidelines): TAP (at 0.1 mg/mL) or Ca(OH)₂ for 2-4 weeks are both acceptable; TAP preferred when avoiding stem cell toxicity is the priority
• For conventional necrotic cases: TAP is a valid alternative to Ca(OH)₂, particularly in refractory infections
• Anterior teeth: Avoid standard TAP due to discoloration risk; use DAP or a minocycline-free formulation
• Duration: Typically 1-4 weeks (shorter duration favored in REPs to preserve stem cells)

Summary

Triple Antibiotic Paste as an Intracanal Medicament

Introduction

Composition

• Conventional use: 1 mg/mL to 1 g/mL
• Regenerative endodontics: 0.1 mg/mL (Galler et al.) - reduced to minimize cytotoxicity

Rationale for Combination

• Gram-positive cocci (Streptococcus, Enterococcus faecalis)
• Gram-negative rods (Fusobacterium nucleatum, Prevotella intermedia)
• Strict anaerobes (Treponema denticola, Porphyromonas gingivalis)
• Facultative anaerobes

• Ciprofloxacin: gram-negative and aerobic coverage
• Metronidazole: anaerobic coverage
• Minocycline: broad-spectrum including gram-positives, spirochetes, and anti-inflammatory activity

Preparation

1. Individual antibiotic tablets are crushed separately into fine powder using a glass slab and spatula
2. Mixed in equal proportions (by weight) on a glass slab
3. Vehicle (macrogol/propylene glycol) added incrementally to achieve a creamy, non-runny paste consistency
4. For REPs: diluted to 0.1 mg/mL by dissolving in saline or distilled water

Placement Technique

1. Canal is instrumented and irrigated with NaOCl (1.25-5.25%) followed by EDTA and saline rinse
2. Canal is dried with paper points
3. TAP delivered using:
   • Lentulo spiral (most common) - rotated counterclockwise during withdrawal
   • Endodontic Explorer/plugger - for apical placement
   • Ultrasonic activation - improves homogeneous distribution
   • Premixed syringe with blunt-end needle - for REP (placed to CEJ level only)
4. Placed 2-4 mm short of the radiographic apex to avoid periapical toxicity
5. Sealed with a temporary restorative material (e.g., Cavit, IRM, glass ionomer)
6. Duration: 2-4 weeks (conventional); 3-4 weeks for REPs per AAE/ESE guidelines

Clinical Applications

1. Conventional Root Canal Treatment

• Inter-appointment dressing for infected root canals with periapical pathology
• Particularly useful in refractory cases where calcium hydroxide has failed (e.g., resistant E. faecalis infections)
• Acute apical abscess with systemic involvement

2. Regenerative Endodontic Procedures (REPs)

• Management of immature permanent teeth with necrotic pulps and open apices
• Goal: achieve canal sterilization without aggressive instrumentation (preserving thin dentine walls)
• Low-concentration TAP (0.1 mg/mL) used to preserve viability of:
  • Dental pulp stem cells (DPSCs)
  • Stem cells from the apical papilla (SCAPs) - critical for continued root development
  • Hertwig's epithelial root sheath (HERS) cells

3. LSTR Therapy (Lesion Sterilization and Tissue Repair)

• Introduced by Takushige et al. (2004) for primary teeth with furcation involvement or periapical lesions
• Canal sterilization by paste placement without mechanical instrumentation
• Reliance on antimicrobial diffusion rather than shaping
• Advantages in uncooperative pediatric patients or teeth with complex root morphology

4. Open Apex Cases (Apexification)

• TAP used as initial disinfecting medicament before MTA apical plug placement
• Provides better bacterial elimination than calcium hydroxide in some studies

5. Internal Root Resorption with Infection

• Used to control infection before obturation or surgical management

Advantages

1. Broad-spectrum antimicrobial activity covering virtually all endodontic pathogens
2. Deep dentinal tubule penetration - particularly ciprofloxacin and minocycline penetrate 800-1000 μm into dentinal tubules (vs. calcium hydroxide which is limited by its ionic diffusion)
3. Anti-biofilm activity - effective against mature biofilms (E. faecalis)
4. Non-instrumentation option - ideal for fragile immature roots in REPs
5. Anti-inflammatory properties - minocycline inhibits MMPs, reducing periapical inflammation
6. Promotes stem cell viability at low concentrations
7. Bactericidal rather than bacteriostatic at clinical concentrations
8. pH near neutral - less irritating to periapical tissues than calcium hydroxide (pH ~12.5)
9. Effective in acidic/anaerobic environment of infected canals - unlike calcium hydroxide which requires alkaline pH for efficacy

Disadvantages and Complications

1. Tooth Discoloration (Major Drawback)

• Cause: Minocycline chelates with iron from hemoglobin breakdown in dentinal tubules, forming dark iron-minocycline complexes
• Appearance: Gray-brown discoloration, predominantly coronally
• Irreversibility: Permanent once set; resistant to bleaching
• Management strategies:
  • Reduce minocycline concentration to 0.01-0.1 mg/mL
  • Replace minocycline with cefaclor, clindamycin, or amoxicillin (forming modified TAP or DAP)
  • Seal dentinal tubules with bonding agent (e.g., dentin adhesive, 5% sodium hypochlorite primer) before TAP application
  • Place TAP below the CEJ in REPs

2. Cytotoxicity

• At high concentrations (1 g/mL), TAP is toxic to:
  • Human periodontal ligament fibroblasts
  • Osteoblasts and osteoclasts
  • SCAPs and DPSCs (most vulnerable to minocycline)
• Solution: Reduce concentration to 0.1 mg/mL for REPs

3. Antibiotic Resistance

• Prolonged use promotes resistance genes in surviving organisms
• Emergence of resistant strains of E. faecalis, Enterobacteriaceae
• Fluoroquinolone resistance (ciprofloxacin) is of particular concern

4. Hypersensitivity

• Allergic reactions to any of the three components (rare but documented)
• Ciprofloxacin: photosensitivity, tendinopathy risk (systemic exposure minimal but possible)
• Minocycline: vestibular side effects, hypersensitivity pneumonitis

5. Drug Interactions

• Minocycline: chelates with divalent cations in irrigants (Ca²⁺ in EDTA solutions) - sequence irrigants before TAP placement
• Can inactivate calcium hydroxide if mixed

6. Incomplete Removal

• TAP is difficult to completely remove from dentinal tubules
• Residual TAP can interfere with epoxy resin sealer adhesion
• Removal protocol: Irrigation with 17% EDTA + NaOCl + ultrasonic activation; passive ultrasonic irrigation (PUI) recommended

Modifications of TAP

TAP vs. Calcium Hydroxide - Comparative Summary

Contraindications

1. Allergy to any component antibiotic
2. Use in vital pulp cases (unnecessary antibiotic exposure)
3. High-concentration TAP in REPs (risk of SCAP destruction)
4. Anterior teeth without precautions against discoloration

Conclusion

• Hoshino E et al. Int Endod J 1996 - Original TAP description
• Takushige T et al. Oral Surg Oral Med Oral Pathol 2004 - LSTR therapy
• AAE Clinical Considerations for REP, 2021
• Alovisi M et al. Int Endod J 2026 - Systematic review PMID 41815050
• Riaz S et al. Biomater Investig Dent 2026 - Narrative review PMID 42057878
• Cohen's Pathways of the Pulp, 12th ed. (Hargreaves & Berman)
• Grossman's Endodontic Practice, 14th ed.